Table 2.
Lesion analysis displaying detection rates and confidence intervals by imaging modalities categorized by total, primary, and metastatic lesions in 11 patients. Further subcategorization of which region the primary and metastatic lesions were located, and their detection rates are shown.
| 68Ga-DOTATATE | 18F-FDG | 18F-FDOPA | CT/MRI | |
|---|---|---|---|---|
| Total Lesions | 249/281 88.6 (84.3–92.1) |
233/281 82.9 (78.0–87.1) |
39/102 39.8 (30.2–50.2) |
157/270 58.2 (52.0–64.1) |
| Primary Lesions | 9/10 90.0 (55.5–99.8) |
9/10 90.0 (55.5–99.8) |
3/7 42.9 (9.9–81.6) |
7/10 70.0 (34.8–93.3) |
| Mediastinum | 1/1 | 1/1 | - vii | 0/1 |
| Adrenal | 1/1 | 1/1 | 0/1 | 1/1 |
| Abdomen/Pelvis | 5/6 | 6/6 | 2/5 | 6/6 |
| Head/Neck | 2/2 | ½ | 1/1 | 0/2 |
| Metastatic Lesions | 240/271 88.6 (84.2–92.1) |
225/271 83.0 (78.0–87.3) |
36/95 37.9 (28.1–48.4) |
150/260 57.7 (51.4–63.8) |
| Bone | 208/223 | 188/223 | 27/64 | 110/212 |
| Lungs | 11/19 | 15/19 | 3/10 | 19/19 |
| Mediastinum | 4/7 | 5/7 | 3/7 | 4/7 |
| Adrenal | 1/1 | 1/1 | 0/1 | 1/1 |
| Liver | 4/7 | 7/7 | 0/4 | 7/7 |
| Abdomen/Pelvis | 6/7 | 6/7 | 2/5 | 4/7 |
| Head/Neck | 6/7 | 3/7 | ¼ | 5/7 |
vii Patient did not receive 18F-FDOPA Imaging due logistics of scheduling.